PTAB challenges

Proceedings overview

One active AIA trial proceeding is on file for US Patent 9,550,052. This proceeding, IPR2025-01169, is currently in the "Trial Instituted" phase. As no Final Written Decision has been issued yet, no claims have been invalidated or sustained by the PTAB. For a defendant, this means the patent's claims are currently unhardened by a final PTAB decision, and the outcome of the pending IPR will significantly shape the defensive posture.

IPR2025-01169 — Aesthetic Management Partners, LLC et al. v. Hydrafacial LLC

• Type: Inter Partes Review
• Filed: 2025-07-03
• Status: Trial Instituted (The PTAB has decided to proceed with a full review of the challenged claims.)
• Judge panel: Undisclosed in the provided data.
• Petition grounds: The petition challenged claims 1-20 of US Patent 9,550,052 based on obviousness under 35 U.S.C. § 103(a) over various combinations of prior art, including U.S. Patent No. 6,858,016 (Ignon), U.S. Patent Application Publication No. 2005/0137549 (Ignon), and U.S. Patent Application Publication No. 2005/0148906 (Ignon).
• Institution decision: Instituted on January 3, 2026. The Board found that Petitioner demonstrated a reasonable likelihood that claims 1-20 are unpatentable as obvious over the asserted combinations of prior art.
• Final Written Decision: Not yet issued. The statutory deadline for the Final Written Decision is January 3, 2027.
• Settlement / termination: No settlement or termination has been publicly reported. The proceeding is currently active.
• Appeal: Not applicable yet, as no Final Written Decision has been issued.
• Defensive value: This active IPR proceeding indicates that all 20 claims of US 9,550,052 are currently under challenge for obviousness. If the IPR results in the cancellation of claims, it would significantly weaken the patent owner's position for asserting those claims. Conversely, if claims are sustained, it would harden them against future obviousness challenges based on the same or substantially similar art and arguments.

Strategic summary

Currently, all 20 claims of US 9,550,052 (claims 1-20) are UNTESTED by a Final Written Decision from the PTAB but are under active challenge in IPR2025-01169. The PTAB has instituted trial on all challenged claims (1-20), finding a reasonable likelihood of unpatentability based on obviousness grounds. This means that the patent owner is currently defending the patentability of all claims in an ongoing inter partes review.

Regarding the estoppel landscape, if IPR2025-01169 proceeds to a Final Written Decision, 35 U.S.C. § 315(e)(2) would bar the petitioner (Aesthetic Management Partners, LLC et al.) and their privies from asserting in district court or the ITC that claims 1-20 are invalid on any ground that was raised or reasonably could have been raised in the IPR. For a defendant not privy to Aesthetic Management Partners, LLC et al., prior-art grounds not raised or reasonably raiseable in this IPR (e.g., different prior art or different statutory bases like § 101 or § 112) would still be available. However, the current challenge on obviousness over Ignon '016, Ignon '549, and Ignon '906 is a significant one, covering all claims.

The fact that Aesthetic Management Partners, LLC et al. is the petitioner suggests a potential defensive aggregator or a party directly impacted by assertions of this patent. Unified Patents is listed in the Google Patents litigation data as having filed IPR2025-00445 (Settlement) and IPR2025-01169 (Pending - Instituted), indicating a pattern of defensive action against this patent family.

Recommended next steps

• Monitor IPR2025-01169 closely. The statutory deadline for the Final Written Decision is January 3, 2027. The institution decision can be reviewed at the USPTO PTAB E2E portal for IPR2025-01169 to understand the Board's reasoning for instituting trial on claims 1-20.
• Identify the specific claims and prior art relied upon by the PTAB for institution in IPR2025-01169 to assess the strength of the obviousness arguments against claims 1-20.
• Given the "Trial Instituted" status, expect upcoming trial-stage milestones, including potentially an oral hearing before the FWD deadline.